Related references
Note: Only part of the references are listed.JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies
Hiroaki Kitaoka et al.
CIRCULATION JOURNAL (2021)
Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
Niels Grote Beverborg et al.
NATURE COMMUNICATIONS (2021)
Genetic Basis and Genotype-Phenotype Correlations in Han Chinese Patients with Idiopathic Dilated Cardiomyopathy
Xin-Lin Zhang et al.
SCIENTIFIC REPORTS (2020)
Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association
Kiran Musunuru et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2020)
The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy (vol 10, 9819, 2020)
Tim R. Eijgenraam et al.
SCIENTIFIC REPORTS (2020)
Mutant KCNJ3 and KCNJ5 Potassium Channels as Novel Molecular Targets in Bradyarrhythmias and Atrial Fibrillation
Noriaki Yamada et al.
CIRCULATION (2019)
Phospholamban cardiomyopathy: aCanadian perspective on aunique population
C. C. Cheung et al.
NETHERLANDS HEART JOURNAL (2019)
Leducq Transatlantic Network of Excellence to Cure Phospholamban-Induced Cardiomyopathy (CURE-PLaN)
Pieter A. Doevendans et al.
CIRCULATION RESEARCH (2019)
Prevalence and cardiac phenotype of patients with aphospholamban mutation
I. E. Hof et al.
NETHERLANDS HEART JOURNAL (2019)
Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals
Elham Kayvanpour et al.
CLINICAL RESEARCH IN CARDIOLOGY (2017)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia
Guan-Sheng Liu et al.
CARDIOVASCULAR RESEARCH (2015)
Outcome in Phospholamban R14del Carriers Results of a Large Multicentre Cohort Study
Ingrid A. W. van Rijsingen et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2014)
Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy
P. A. van der Zwaag et al.
NETHERLANDS HEART JOURNAL (2013)
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy
Paul A. van der Zwaag et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Hydrophobic Imbalance in the Cytoplasmic Domain of Phospholamban Is a Determinant for Lethal Dilated Cardiomyopathy
Delaine K. Ceholski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Mutations in the human phospholamban gene in patients with heart failure
Alessandra Medeiros et al.
AMERICAN HEART JOURNAL (2011)
Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes
Maximilian G. Posch et al.
HEART RHYTHM (2009)
Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy
Megan M. DeWitt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy
K Haghighi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban
JP Schmitt et al.
SCIENCE (2003)
Share Paper
